Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

被引:48
|
作者
Farina, C
Vargas, V
Heydari, N
Kümpfel, T
Meinl, E
Hohlfeld, R
机构
[1] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[2] Univ Munich, Inst Clin Neuroimmunol, D-81366 Munich, Germany
关键词
multiple sclerosis; auto immunity; TH2-lymphocytes;
D O I
10.1016/S0165-5728(01)00490-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells. (C) 2002 Elsevier Science B.V All tights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [31] Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
    Taskapilioglu, Ozlem
    Turan, Asli Bahar
    Albas, Murat
    Turan, Omer Faruk
    TURKISH JOURNAL OF NEUROLOGY, 2012, 18 (01) : 17 - 20
  • [32] INSULIN INDUCES PREDOMINANTLY IGG3 AND IGG4 ANTIBODIES
    KUMAR, D
    CLINICAL RESEARCH, 1986, 34 (01): : A104 - A104
  • [33] Long Term Treatment of Multiple Sclerosis with Glatiramer Acetate: Natural History of the Subtypes of Anti-Glatiramer Acetate Antibodies and Their Correlation with Clinical Efficacy
    Brenner, Talma
    Teitelbaum, Dvora
    Sicsic, Camille
    Karussis, Dimitrios
    NEUROLOGY, 2010, 74 (09) : A423 - A423
  • [34] Treatment with glatiramer acetate (GA) induces and restores CD8+T-cell responses in patients with multiple sclerosis
    Karandikar, NJ
    Crawford, MP
    Ratts, RB
    Brenchley, JM
    Ambrozak, DR
    Lovett-Racke, AE
    Douek, DC
    Koup, RA
    Racke, MK
    NEUROLOGY, 2002, 58 (07) : A246 - A246
  • [35] Glatiramer acetate-specific human CD8+T cells:: Increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment
    Dressel, Alexander
    Vogelgesang, Antje
    Brinkmeier, Heinrich
    Maeder, Michael
    Weber, Frank
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 181 (1-2) : 133 - 140
  • [36] Treatment Challenges in Multiple Sclerosis - A Continued Role for Glatiramer Acetate?
    Mirabella, Massimiliano
    Annovazzi, Pietro
    Brownlee, Wallace
    Cohen, Jeffrey A.
    Kleinschnitz, Christoph
    Wolf, Christian
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [37] Glatiramer acetate in multiple sclerosis: A review
    Ruggieri, Maddalena
    Avolio, Carlo
    Livrea, Paolo
    Trojano, Maria
    CNS DRUG REVIEWS, 2007, 13 (02): : 178 - 191
  • [38] Lipoatrophy associated with glatiramer acetate injections for the treatment of multiple sclerosis
    Hwang, L
    Orengo, I
    CUTIS, 2001, 68 (04): : 287 - 288
  • [39] Glatiramer acetate for relapsing multiple sclerosis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1997, 39 (1004): : 61 - 62
  • [40] Glatiramer acetate for treatment of relapsing-remitting multiple sclerosis
    Johnson, Kenneth P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (04) : 371 - 384